The tweet was deleted by the author.
But we saved everything 🙂.
CME Group released its latest Equity Insights report. The report states that single stock futures will arrive on July 27 in both larger and Micro sizes, pending approval.
The report adds that AIR TRF open interest has surpassed 1 million contracts. Morningstar has also joined the E-mini futures suite.
CME Group is trading at $245.97, which places the price above the MA-20 ($237.12) but below both MA-50 ($260.19) and MA-200 ($279.11). This setup signals short-term bullish momentum, while medium- and long-term trend pressure remains with the sellers. The Ichimoku Kijun on D1 stands at $243.95, representing immediate support for the current price. Near-term support is at $243.95 (Kijun), with key support emerging at $237.12 (MA-20). Near-term resistance sits at $260.19 (MA-50), while $279.11 (MA-200) acts as key long-term resistance.
Momentum signals are mixed: MACD on D1 indicates strong bearish momentum, while ADX signals an ongoing sell bias with trend strength. RSI on D1 is moderately weak at 48.82, and CCI leans bullish at 69.62. Stoch RSI and BBP both highlight overbought conditions, with the latter showing clear dominance by buyers. Awesome Oscillator remains neutral, suggesting uncertainty in directional conviction. Over the past week, CME has risen $0.92 (0.38%) from the previous close of $245.05, currently trading in the upper part of its weekly range. Weekly volatility stands at 2.50%. The current tone is consolidation near recent highs, reflecting a mild recovery from the weekly low.
Looking ahead, the expected price range for CME over the next week is $242.00–$248.00, reflecting typical volatility around the current price and keeping within 20% of the present value. This range remains closer to the lower end of the 52-week window ($218.31–$329.16), underscoring lingering long-term weakness. Based on weekly indicators—specifically the persistent sell signals from RSI, MACD, and MA-50 on W1—the probability of a further decline is very high (more than 80%), while an upward breakout is less likely. The baseline scenario sees CME continuing to consolidate between support at $243.95 and resistance near $248.00. A bullish scenario would require a break above $248.00, targeting MA-50 levels, while a bearish outcome could see the price testing and possibly breaching near-term support at $243.95, opening the way to $237.12.
In a recent review, CME Group was observed to be regaining technical strength, with momentum indicators pointing to renewed buying interest after a period of weakness. As the current analysis builds on these findings, traders should focus on identifying confirmation of sustained bullish momentum as the key driver for the next phase in CME Group's price action.